Cancer Center's lymphoma specialist, Dr. Palomba, provides an in-depth look at how CAR T-cell therapy is evolving to offer hope for more patients battling hematologic malignancies.

Psoriasis was less likely to progress to psoriatic arthritis (PsA) among patients treated with interleukin-17 (IL-17) or ...

The FDA has granted a fast track designation to rezpegaldesleukin for treating patients aged 12 years and older with moderate ...

Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has announced significant findings about ATI-2138, a novel investigational drug ...

Work at Exelixis Inc. has led to the development of antibody-drug conjugates (ADCs) comprising antibodies targeting interleukin-13 receptor subunit α2 (IL-13RA2, IL-13R-α2) covalently linked to a ...

Within the immune system, interleukin-15 (IL-15) plays a relevant role by boosting the number of cytotoxic T cells and NK cells, the major drivers of anticancer immune response. Researchers from Sotio ...

The RNA inhibitor olpasiran significantly reduces a type of "bad cholesterol" that's associated with a high risk of ...

The use of biologics in psoriasis and psoriatic arthritis management is not linked to the risk of cardiovascular or venous thromboembolic events.

Aclaris Therapeutics (ACRS) announced the availability of a new publication describing properties of Aclaris Therapeutics’ ATI-2138, a novel ...

Analysis by Mount Sinai researcher from First-of-its kind global trial could lead to future therapies to prevent deadly ...

Researchers from Rice University and Baylor College of Medicine have developed a new treatment that eliminates advanced-stage ...

Exposure to TNF inhibitors was linked to a reduced risk for cardiovascular events among patients with AS; the impact of IL-17 inhibitors was less clear.